Members of the TRiNDS team, including its board of directors, have a long-term commitment to translational research and drug development in the neuromuscular community. They represent key opinion leaders from the bench to the bedside. The TRiNDS team has played central roles in the design and management of important studies such as the CINRG Duchenne Natural History Study (DNHS), the largest longitudinal controlled study of patients with Duchenne across the age range.
TRiNDS was formed by colleagues at several academic centers that are part of the CINRG network. The TRiNDS team builds on strong leadership skills and is focused on providing efficient services to pharmaceutical and biotechnology industries as well as academic investigators. TRiNDS combines international disease expertise with regulatory agency compliant data and project management solutions as well as study design and data interpretation.
The TRiNDS team has standard operating procedures (SOP) established for:
TRiNDS domain expertise and research knowledge fill an emerging need in drug development and clinical trials for rare and orphan disease such as neuromuscular diseases.
The TRiNDS team has experience in the following neuromuscular diseases: